Join
Live feed
·
PRReleasevia Quantisnow
Inhibrx Biosciences Inc. logo

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

ByQuantisnow·Wall Street's wire, on your screen.
INBX· Inhibrx Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INBX (Inhibrx Biosciences Inc.) and more on Quantisnow.